Acid-sensitive Lipidated Doxorubicin Prodrug Entrapped in Nanoemulsion Impairs Lung Tumor Metastasis in a Breast Cancer Model

Ana Lygia dos Santos Câmara, Gregor Nagel, Harald Rune Tschiche, Camila Magalhães Cardador, Luís Alexandre Muehlmann, Daniela Mara de Oliveira, Paula Queiroz Alvim, Ricardo Bentes Azevedo, Marcelo Calderón, João Paulo Figueiró Longo

Nanomedicine · 2017 · 39 citations · 25 references

Concepts

Abstract

AIM: To develop an acid-sensitive lipidated, doxorubicin (Dox) prodrug (C16-Dox) to be entrapped in lipid nanoemulsion (NE-C16-Dox) as a nanocarrier to treat breast cancer models (in vitro and in vivo). RESULTS: We report the efficacy of NE-C16-Dox in in vitro experiments, as well as the improved chemotherapeutic index and tumor-control efficacy compared with treatment with free Dox in an in vivo murine 4T1 breast cancer model. In addition, NE-C16-Dox allowed the use of a higher dose of Dox, acceptable biocompatibility and a significant reduction in lung metastasis. CONCLUSION: Taken together, these results indicate that NE-C16-Dox is promising for breast cancer treatment, thus creating possibilities to translate these nanotechnology concepts to clinical applications.

References

25